SG Americas Securities LLC Buys 11,779 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

SG Americas Securities LLC grew its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 61.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,889 shares of the company’s stock after purchasing an additional 11,779 shares during the period. SG Americas Securities LLC’s holdings in Lineage Cell Therapeutics were worth $34,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in LCTX. Vanguard Group Inc. lifted its stake in shares of Lineage Cell Therapeutics by 16.1% in the 3rd quarter. Vanguard Group Inc. now owns 8,312,332 shares of the company’s stock valued at $9,809,000 after acquiring an additional 1,150,633 shares during the last quarter. Deutsche Bank AG increased its holdings in Lineage Cell Therapeutics by 622.5% in the 3rd quarter. Deutsche Bank AG now owns 79,094 shares of the company’s stock worth $93,000 after purchasing an additional 68,147 shares in the last quarter. Northern Trust Corp raised its position in Lineage Cell Therapeutics by 9.1% in the third quarter. Northern Trust Corp now owns 1,203,957 shares of the company’s stock valued at $1,421,000 after purchasing an additional 100,825 shares during the last quarter. Rathbones Group PLC acquired a new stake in shares of Lineage Cell Therapeutics during the third quarter valued at about $41,000. Finally, HighTower Advisors LLC grew its holdings in shares of Lineage Cell Therapeutics by 58.5% during the third quarter. HighTower Advisors LLC now owns 54,071 shares of the company’s stock worth $64,000 after purchasing an additional 19,955 shares during the last quarter. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Trading Down 4.2 %

Shares of LCTX stock opened at $1.15 on Monday. The company has a market capitalization of $216.81 million, a P/E ratio of -8.85 and a beta of 1.31. Lineage Cell Therapeutics, Inc. has a one year low of $0.84 and a one year high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Lineage Cell Therapeutics had a negative net margin of 240.20% and a negative return on equity of 31.95%. The firm had revenue of $2.09 million for the quarter, compared to the consensus estimate of $4.74 million. As a group, sell-side analysts anticipate that Lineage Cell Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on LCTX shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, February 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $6.00 price objective on shares of Lineage Cell Therapeutics in a report on Monday, February 5th.

Insider Activity at Lineage Cell Therapeutics

In other Lineage Cell Therapeutics news, Director Broadwood Partners, L.P. bought 6,730,770 shares of the business’s stock in a transaction that occurred on Tuesday, February 6th. The shares were bought at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the transaction, the director now directly owns 41,666,255 shares in the company, valued at $43,332,905.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Broadwood Partners, L.P. acquired 6,730,770 shares of the stock in a transaction dated Tuesday, February 6th. The stock was bought at an average price of $1.04 per share, for a total transaction of $7,000,000.80. Following the purchase, the director now directly owns 41,666,255 shares of the company’s stock, valued at approximately $43,332,905.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Don M. Bailey bought 96,155 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The shares were bought at an average price of $1.04 per share, for a total transaction of $100,001.20. Following the transaction, the director now directly owns 158,801 shares in the company, valued at $165,153.04. The disclosure for this purchase can be found here. 28.10% of the stock is owned by company insiders.

Lineage Cell Therapeutics Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.